Reports Q2 revenue $8.07M, consensus $11.03M. Phillip Chan, CEO of CytoSorbents stated, “We are pleased to report another successful quarter of executing on our three key business objectives for 2023. Most importantly, we expect to complete the pivotal STAR-T randomized, controlled trial imminently, following the 30-day follow-up of the last patient, which we believe puts us on target for topline data before the end of the year.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CTSO:
- CytoSorbents Reports Second Quarter 2023 Financial and Operational Results
- Cytosorbents Corp (CTSO) Q2 Earnings Cheat Sheet
- CytoSorbents to Report Second Quarter 2023 Operating and Financial Results
- CytoSorbents Appoints Alexander D’Amico as Chief Financial Officer
- CytoSorbents appoints D’Amico as Chief Financial Officer